GB0516091D0 - Therapeutic agent - Google Patents

Therapeutic agent

Info

Publication number
GB0516091D0
GB0516091D0 GBGB0516091.6A GB0516091A GB0516091D0 GB 0516091 D0 GB0516091 D0 GB 0516091D0 GB 0516091 A GB0516091 A GB 0516091A GB 0516091 D0 GB0516091 D0 GB 0516091D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agent
therapeutic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0516091.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemostatix Ltd
Original Assignee
Haemostatix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemostatix Ltd filed Critical Haemostatix Ltd
Priority to GBGB0516091.6A priority Critical patent/GB0516091D0/en
Publication of GB0516091D0 publication Critical patent/GB0516091D0/en
Priority to AU2006274685A priority patent/AU2006274685A1/en
Priority to EP06765236.2A priority patent/EP1919508B1/en
Priority to CA002625917A priority patent/CA2625917A1/en
Priority to US11/997,540 priority patent/US20090203619A1/en
Priority to EP10196237.1A priority patent/EP2335737A3/en
Priority to CNA2006800348757A priority patent/CN101267843A/zh
Priority to PCT/GB2006/002934 priority patent/WO2007015107A2/en
Priority to JP2008524591A priority patent/JP2009505964A/ja
Priority to GB0615545.1A priority patent/GB2429153C/en
Priority to IL189105A priority patent/IL189105A0/en
Priority to US13/408,897 priority patent/US20130029913A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB0516091.6A 2005-08-04 2005-08-04 Therapeutic agent Ceased GB0516091D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0516091.6A GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent
GB0615545.1A GB2429153C (en) 2005-08-04 2006-08-04 Artificial platelets
US11/997,540 US20090203619A1 (en) 2005-08-04 2006-08-04 Artificial platelets
EP06765236.2A EP1919508B1 (en) 2005-08-04 2006-08-04 Artificial platelets
CA002625917A CA2625917A1 (en) 2005-08-04 2006-08-04 Artificial platelets
AU2006274685A AU2006274685A1 (en) 2005-08-04 2006-08-04 Artificial platelets
EP10196237.1A EP2335737A3 (en) 2005-08-04 2006-08-04 Artificial platelets
CNA2006800348757A CN101267843A (zh) 2005-08-04 2006-08-04 人造血小板
PCT/GB2006/002934 WO2007015107A2 (en) 2005-08-04 2006-08-04 Artificial platelets
JP2008524591A JP2009505964A (ja) 2005-08-04 2006-08-04 人工血小板
IL189105A IL189105A0 (en) 2005-08-04 2008-01-29 Artificial platelets
US13/408,897 US20130029913A1 (en) 2005-08-04 2012-02-29 Artificial platelets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0516091.6A GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent

Publications (1)

Publication Number Publication Date
GB0516091D0 true GB0516091D0 (en) 2005-09-14

Family

ID=34984119

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0516091.6A Ceased GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent
GB0615545.1A Expired - Fee Related GB2429153C (en) 2005-08-04 2006-08-04 Artificial platelets

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0615545.1A Expired - Fee Related GB2429153C (en) 2005-08-04 2006-08-04 Artificial platelets

Country Status (9)

Country Link
US (2) US20090203619A1 (https=)
EP (2) EP2335737A3 (https=)
JP (1) JP2009505964A (https=)
CN (1) CN101267843A (https=)
AU (1) AU2006274685A1 (https=)
CA (1) CA2625917A1 (https=)
GB (2) GB0516091D0 (https=)
IL (1) IL189105A0 (https=)
WO (1) WO2007015107A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623607D0 (en) * 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
EP2120989A1 (en) * 2007-03-21 2009-11-25 DSM IP Assets B.V. Cholesterol lowering protein hydrolysates
WO2009046845A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a lactoferrin partial peptide peptide as a therapeutic agent
KR20100057642A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃｎｐ-２２ 단독 또는 피살라에민과 배합된 이의 용도
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
WO2014197816A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
SG10201710616XA (en) * 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
WO2015073418A2 (en) * 2013-11-15 2015-05-21 President And Fellows Of Harvard College Methods and assays for factor viii activity
GB201400292D0 (en) * 2014-01-08 2014-02-26 Haemostatix Ltd Peptide dendrimers and agents
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
CN107686506B (zh) * 2016-08-05 2021-03-30 首都医科大学 华法林-4-o-乙酰-gprp,其合成,活性和应用
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN108976285B (zh) * 2017-05-31 2021-11-30 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
CN108976284B (zh) * 2017-05-31 2021-11-30 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
JP7320599B2 (ja) * 2018-04-24 2023-08-03 フィブリアント・ベスローテン・フェンノートシャップ フィブリノーゲンガンマプライム変種の治療的使用
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
CN115010784B (zh) * 2022-05-16 2023-03-31 江南大学 一种ace抑制肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
ATE329624T1 (de) * 1992-05-21 2006-07-15 Diatide Inc Technetium-99m markierte peptide zur bilderzeugung von thrombus
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
DE69526665T2 (de) * 1994-09-21 2002-11-21 Cytogen Corp., Princeton Antigen bindende peptide (abtides) aus peptidbibliotheken
ES2232862T3 (es) * 1996-10-21 2005-06-01 Quadrant Drug Delivery Limited Sustitutos de plaquetas y procedimientos de conjugacion apropiados para su preparacion.
WO1998055105A1 (en) * 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
DK9700423U3 (da) * 1997-11-10 1999-03-12 Simatek A S Multifunktion cip-dyse
WO1999042146A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0413346D0 (en) * 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing

Also Published As

Publication number Publication date
EP1919508B1 (en) 2015-02-25
EP1919508A2 (en) 2008-05-14
EP2335737A2 (en) 2011-06-22
IL189105A0 (en) 2008-08-07
CN101267843A (zh) 2008-09-17
US20090203619A1 (en) 2009-08-13
JP2009505964A (ja) 2009-02-12
GB0615545D0 (en) 2006-09-13
AU2006274685A1 (en) 2007-02-08
WO2007015107A2 (en) 2007-02-08
WO2007015107A3 (en) 2007-07-26
GB2429153C (en) 2019-01-23
GB2429153A (en) 2007-02-21
US20130029913A1 (en) 2013-01-31
CA2625917A1 (en) 2007-02-08
EP2335737A3 (en) 2013-09-25
GB2429153B (en) 2010-03-10

Similar Documents

Publication Publication Date Title
PT3424932T (pt) Boronoftalidas para utilização terapêutica
GB0506147D0 (en) Therapeutic agents
GB0521139D0 (en) Therapeutic agent
GB0516091D0 (en) Therapeutic agent
PL2601972T3 (pl) Nielitotrypsyjne leczenie kamieni nerkowych
GB0519797D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
GB0518819D0 (en) Therapeutic agents
GB0519350D0 (en) Therapeutic agents
ZA200709627B (en) Combination therapy
GB0518817D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
GB0507003D0 (en) Therapeutic
GB0501655D0 (en) Therapeutic use
GB0518720D0 (en) Therapeutic combination
GB0523998D0 (en) Therapeutic agents
GB0508153D0 (en) Therapeutic agent
GB0522433D0 (en) Therapeutic agents
GB0516732D0 (en) Therapeutic agent
GB0519659D0 (en) Therapeutic agents
GB0525124D0 (en) Therapeutic agents
GB0521538D0 (en) Therapeutic agents
GB0516787D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)